Blood marker study halted: could uPAR predict drug success?
NCT ID NCT02125617
First seen Jan 16, 2026 · Last updated May 16, 2026 · Updated 18 times
Summary
This study aimed to see if a substance in the blood called uPAR could help doctors predict whether men with advanced prostate cancer would respond to the drug abiraterone. Only 3 men were enrolled before the study was stopped early. The goal was to find a simple blood test to guide treatment decisions, but the small size means no firm conclusions can be drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University Hospital of Copenhagen, Rigshospitalet
Copenhagen, 2100, Denmark
Conditions
Explore the condition pages connected to this study.